Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

Home
/
update
/
details

CS Genetics and ROSALIND® Join Forces to Expand Access to Single-Cell Genomics

NextEdge Admin

20 Sep 2024

2 min 10 sec

CS Genetics, a genomics technology company, has announced a strategic partnership with ROSALIND®, a leading SaaS platform in life science research. This collaboration merges the simplicity of CS Genetics' SimpleCell™ platform with ROSALIND®'s advanced multi-omics analysis, providing researchers with expanded single-cell capabilities at a significantly reduced cost.

Jay Harger, Chief Operating Officer of CS Genetics, emphasized that the SimpleCell™ platform redefines single-cell genomics by eliminating the need for costly instruments and drastically lowering per-sample expenses. "Our partnership with ROSALIND® allows biopharma and academic teams to undertake larger, more rigorous single-cell projects while benefiting from top-tier analysis and collaboration tools," he stated.

The SimpleCell™ platform employs a novel, instrument-free approach powered by Kinetic Confinement, integrating seamlessly into standard lab workflows. This enables biopharma and academic researchers to conduct larger-scale studies with greater speed and cost efficiency.

Tim Wesselman, CEO of ROSALIND®, highlighted that CS Genetics addresses key barriers to single-cell genomics: complexity and cost. He noted that this collaboration not only accelerates research but also maximizes return on investment by empowering more projects and fostering larger scientific teams.

Together, CS Genetics and ROSALIND® aim to democratize single-cell genomics, making this technology accessible to more researchers while enhancing scientific discovery and collaboration.

CS Genetics is based in Cambridge, UK, and San Diego, CA, and specializes in innovative, scalable genomics solutions.